Official Title
Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails
Brief Summary

There is still controversy about the effective of glucocorticoids for the treatment of novel coronavirus pneumonia. This is a prospective randomized controlled trails. The aim is to explore the effectiveness and safety of glucocorticoids in the treatment of novel coronavirus pneumonia.

Completed
COVID-19
Novel Coronavirus Pneumonia

Drug: Methylprednisolone

Methylprednisolone 1mg/kg/day ivgtt for 7 days.

Eligibility Criteria

Inclusion Criteria:

- age more than 18 years old

- accord with the clinical diagnosis and/ or etiological diagnosis diagnostic criteria
of Novel coronavirus pneumonia (COVID-19).

- admitted in the general wards

- be able to sign informed consent

Exclusion Criteria:

- severe immunosuppression (HIV infection, long-term use of immunosuppressive agents

- pregnant or lactation period women

- glucocorticoids are needed for other diseases

- unwilling or unable to participate or complete the study

- participate in other study

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
China
Locations

Hubei province hospital of integrated Chinese & Western Medicine
Wuhan, Hubei, China

Yichang first people's Hospital
Yichang, Hubei, China

Beijing YouAn Hospital
Beijing, China

Renmin Hospital of Wuhan University
Wuhan, China

Tianyou Hospital Affiliated to Wuhan University of science and technology
Wuhan, China

Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology
Wuhan, China

the first peopel hospital of Xiangyang
Xiangyang, China

Beijing Chao Yang Hospital
NCT Number
MeSH Terms
COVID-19
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate